Twin Tree Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,891
| Closed | -$2.57M | – | 1784 |
|
|
2025
Q2 | $2.57M | Buy |
+4,891
| New | +$2.73M | ﹤0.01% | 1195 |
|
|
2024
Q4 | – | Sell |
-155
| Closed | -$130K | – | 1865 |
|
|
2024
Q3 | $163K | Sell |
155
-8,887
| -98% | -$9.89M | ﹤0.01% | 1363 |
|
|
2024
Q2 | $9.5M | Sell |
9,042
-1,537
| -15% | -$1.49M | 0.02% | 586 |
|
|
2024
Q1 | $10.2M | Sell |
10,579
-3,399
| -24% | -$3.23M | 0.02% | 641 |
|
|
2023
Q4 | $12.3M | Buy |
+13,978
| New | +$11.5M | 0.02% | 631 |
|
|
2023
Q3 | – | Sell |
-2,532
| Closed | -$1.82M | – | 1478 |
|
|
2023
Q2 | $1.82M | Sell |
2,532
-31,504
| -93% | -$24.3M | ﹤0.01% | 940 |
|
|
2023
Q1 | $28M | Buy |
34,036
+15,252
| +81% | +$11.5M | 0.05% | 307 |
|
|
2022
Q4 | $13.6M | Sell |
18,784
-18,850
| -50% | -$13.9M | 0.03% | 489 |
|
|
2022
Q3 | $25.9M | Buy |
+37,634
| New | +$23.7M | 0.05% | 316 |
|
|
2022
Q1 | – | Sell |
-845
| Closed | -$534K | – | 1849 |
|
|
2021
Q4 | $534K | Sell |
845
-28,632
| -97% | -$17.6M | ﹤0.01% | 1330 |
|
|
2021
Q3 | $17.8M | Buy |
29,477
+1,415
| +5% | +$878K | 0.04% | 399 |
|
|
2021
Q2 | $15.7M | Buy |
28,062
+23,178
| +475% | +$11.7M | 0.04% | 395 |
|
|
2021
Q1 | $2.31M | Buy |
+4,884
| New | +$2.38M | 0.01% | 814 |
|
|
2020
Q4 | – | Sell |
-1,757
| Closed | -$948K | – | 1458 |
|
|
2020
Q3 | $984K | Sell |
1,757
-3,587
| -67% | -$2.17M | ﹤0.01% | 900 |
|
|
2020
Q2 | $3.33M | Sell |
5,344
-4,352
| -45% | -$2.47M | 0.01% | 752 |
|
|
2020
Q1 | $4.73M | Buy |
+9,696
| New | +$4M | 0.02% | 502 |
|
|
2019
Q2 | – | Sell |
-4,967
| Closed | -$2.04M | – | 1503 |
|
|
2019
Q1 | $2.04M | Buy |
+4,967
| New | +$2.05M | 0.01% | 671 |
|
|
2018
Q3 | – | Sell |
-23,082
| Closed | -$8.78M | – | 1260 |
|
|
2018
Q2 | $7.96M | Buy |
+23,082
| New | +$7.22M | 0.05% | 314 |
|
|
2018
Q1 | – | Sell |
-7,879
| Closed | -$2.74M | – | 1274 |
|
|
2017
Q4 | $2.96M | Buy |
7,879
+7,482
| +1,885% | +$3.03M | 0.02% | 516 |
|
|
2017
Q3 | $178K | Buy |
+397
| New | +$189K | ﹤0.01% | 831 |
|
|
2017
Q2 | – | Sell |
-28,945
| Closed | -$12.7M | – | 1130 |
|
|
2017
Q1 | $11.2M | Buy |
28,945
+24,442
| +543% | +$9.06M | 0.1% | 206 |
|
|
2016
Q4 | $1.65M | Sell |
4,503
-10,029
| -69% | -$3.81M | 0.02% | 674 |
|
|
2016
Q3 | $5.84M | Buy |
14,532
+9,751
| +204% | +$3.91M | 0.07% | 261 |
|
|
2016
Q2 | $1.67M | Buy |
4,781
+1,397
| +41% | +$538K | 0.03% | 525 |
|
|
2016
Q1 | $1.22M | Buy |
3,384
+2,237
| +195% | +$922K | 0.02% | 546 |
|
|
2015
Q4 | $623K | Buy |
1,147
+351
| +44% | +$190K | 0.01% | 794 |
|
|
2015
Q3 | $370K | Buy |
796
+702
| +747% | +$377K | 0.01% | 868 |
|
|
2015
Q2 | $48K | Sell |
94
-655
| -87% | -$320K | ﹤0.01% | 1211 |
|
|
2015
Q1 | $338K | Buy |
+749
| New | +$317K | 0.01% | 882 |
|
|
2014
Q3 | – | Sell |
-3,186
| Closed | -$1.07M | – | 1094 |
|
|
2014
Q2 | $900K | Buy |
+3,186
| New | +$944K | 0.02% | 594 |
|
|
2013
Q3 | – | Sell |
-1,201
| Closed | -$270K | – | 881 |
|
|
2013
Q2 | $270K | Buy |
+1,201
| New | +$280K | 0.01% | 677 |
|
Other funds holding REGN
Twin Tree Management's REGN Position: Q3 2025 in Review
Twin Tree Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 4,891 shares — an estimated $2.57M sold.
Twin Tree Management first reported a position in REGN in Q2 2013 and held it in 31 quarters. The position peaked at $28M in Q1 2023. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.
- Twin Tree Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Twin Tree Management sold 4,891 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $2.57M.
- Twin Tree Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 31 quarters.
- Twin Tree Management's Regeneron Pharmaceuticals position peaked at $28M in Q1 2023.
- 1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.
Based on Twin Tree Management's 13F filing for Q3 2025, filed 13 Nov 2025.